A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects

Alrouji, Mohammed; Al-Kuraishy, Hayder M; Al-Gareeb, Ali I; Saad, Hebatallah M.; Batiha, Gaber El‐Saber

doi:10.1007/s10787-023-01192-2

Cited by 22 publications

(8 citation statements)

References 182 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, treatments might target mitochondrial function, α-synuclein build up, microglial activation and inflammatory processes. For example, it has been reported that non-steroidal anti-inflammatory drugs (NSAIDs) might somewhat reduce the risk of developing Parkinson's disease [33].…”

Section: Neurodegenerationmentioning

confidence: 99%

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Bicknell,

Liebert,

Herkes

2024

JPM

View full text Add to dashboard Cite

Parkinson’s disease is the second most common neurodegenerative disease and is increasing in incidence. The combination of motor and non-motor symptoms makes this a devastating disease for people with Parkinson’s disease and their care givers. Parkinson’s disease is characterised by mitochondrial dysfunction and neuronal death in the substantia nigra, a reduction in dopamine, accumulation of α-synuclein aggregates and neuroinflammation. The microbiome–gut–brain axis is also important in Parkinson’s disease, involved in the spread of inflammation and aggregated α-synuclein. The mainstay of Parkinson’s disease treatment is dopamine replacement therapy, which can reduce some of the motor signs. There is a need for additional treatment options to supplement available medications. Photobiomodulation (PBM) is a form of light therapy that has been shown to have multiple clinical benefits due to its enhancement of the mitochondrial electron transport chain and the subsequent increase in mitochondrial membrane potential and ATP production. PBM also modulates cellular signalling and has been shown to reduce inflammation. Clinically, PBM has been used for decades to improve wound healing, treat pain, reduce swelling and heal deep tissues. Pre-clinical experiments have indicated that PBM has the potential to improve the clinical signs of Parkinson’s disease and to provide neuroprotection. This effect is seen whether the PBM is directed to the head of the animal or to other parts of the body (remotely). A small number of clinical trials has given weight to the possibility that using PBM can improve both motor and non-motor clinical signs and symptoms of Parkinson’s disease and may potentially slow its progression.

show abstract

Section: Neurodegenerationmentioning

confidence: 99%

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Bicknell,

Liebert,

Herkes

2024

JPM

View full text Add to dashboard Cite

show abstract

“… 12 PD is distinguished by motor manifestations such as tremors, rigidity, postural instability and bradykinesia. 13 In PD, non‐motor symptoms such as dementia, cognitive dysfunction, sleep disorders and depression may emerge several decades before the advancement of motor symptoms. 14 , 15 Among people over 60, PD affects 1%–3% of the population.…”

Section: Pathogenesis and Clinical Feature Of Pdmentioning

confidence: 99%

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Ali,

Al‐Kuraishy,

Al‐Gareeb

et al. 2024

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Parkinson's disease (PD) is a neurodegenerative disorder of the brain and is manifested by motor and non‐motor symptoms because of degenerative changes in dopaminergic neurons of the substantia nigra. PD neuropathology is associated with mitochondrial dysfunction, oxidative damage and apoptosis. Thus, the modulation of mitochondrial dysfunction, oxidative damage and apoptosis by growth factors could be a novel boulevard in the management of PD. Brain‐derived neurotrophic factor (BDNF) and its receptor tropomyosin receptor kinase type B (TrkB) are chiefly involved in PD neuropathology. BDNF promotes the survival of dopaminergic neurons in the substantia nigra and enhances the functional activity of striatal neurons. Deficiency of the TrkB receptor triggers degeneration of dopaminergic neurons and accumulation of α‐Syn in the substantia nigra. As well, BDNF/TrkB signalling is reduced in the early phase of PD neuropathology. Targeting of BDNF/TrkB signalling by specific activators may attenuate PD neuropathology. Thus, this review aimed to discuss the potential role of BDNF/TrkB activators against PD. In conclusion, BDNF/TrkB signalling is decreased in PD and linked with disease severity and long‐term complications. Activation of BDNF/TrkB by specific activators may attenuate PD neuropathology.

show abstract

“… 23 Induction of PD neuropathology is related to the genetic and environmental factors in genetically susceptible subjects. 24 Genetic mutations promote the development and progression of familial PD; however, environmental factors are more related in the development of sporadic PD. Most of PD cases are sporadic in about 90%, though 10% of PD is familial.…”

Section: Role Of Cdk5 In Pdmentioning

confidence: 99%

“…High metabolic rate of dopaminergic neurons in the SNpc promote generation of reactive oxygen species (ROS) result in oxidative stress which also induce neurodegeneration 23 . Induction of PD neuropathology is related to the genetic and environmental factors in genetically susceptible subjects 24 . Genetic mutations promote the development and progression of familial PD; however, environmental factors are more related in the development of sporadic PD.…”

Section: Role Of Cdk5 In Pdmentioning

confidence: 99%

Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease

Alrouji,

Al‐kuraishy,

Al‐Gareeb

et al. 2024

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Cyclin‐dependent kinase 5 (Cdk5) is a protein expressed in postmitotic neurons in the central nervous system (CNS). Cdk5 is activated by p35 and p39 which are neuron regulatory subunits. Cdk5/p35 complex is activated by calpain protease to form Cdk5/p35 which has a neuroprotective effect by regulating the synaptic plasticity and memory functions. However, exaggerated Cdk5 is implicated in different types of neurodegenerative diseases including Parkinson disease (PD). Therefore, modulation of Cdk5 signalling may mitigate PD neuropathology. Therefore, the aim of the present review was to discuss the critical role of Cdk5 in the pathogenesis of PD, and how Cdk5 inhibitors are effectual in the management of PD. In conclusion, overactivated Cdk5 is involved the development of neurodegeneration, and Cdk5/calpain inhibitors such as statins, metformin, fenofibrates and rosiglitazone can attenuate the progression of PD neuropathology.

show abstract

A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease: beneficial or detrimental effects

Cited by 22 publications

References 182 publications

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

Parkinson’s Disease and Photobiomodulation: Potential for Treatment

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease

Contact Info

Product

Resources

About